CA3108800A1 - Salts and crystal forms of omecamtiv mecarbil - Google Patents
Salts and crystal forms of omecamtiv mecarbil Download PDFInfo
- Publication number
- CA3108800A1 CA3108800A1 CA3108800A CA3108800A CA3108800A1 CA 3108800 A1 CA3108800 A1 CA 3108800A1 CA 3108800 A CA3108800 A CA 3108800A CA 3108800 A CA3108800 A CA 3108800A CA 3108800 A1 CA3108800 A1 CA 3108800A1
- Authority
- CA
- Canada
- Prior art keywords
- omecamtiv mecarbil
- peaks
- radiation
- xrpd
- crystalline salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/07—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton
- C07C309/08—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing oxygen atoms bound to the carbon skeleton containing hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
- C07C65/10—Salicylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765090P | 2018-08-17 | 2018-08-17 | |
| US62/765,090 | 2018-08-17 | ||
| PCT/US2019/046726 WO2020037164A1 (en) | 2018-08-17 | 2019-08-16 | Salts and crystal forms of omecamtiv mecarbil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3108800A1 true CA3108800A1 (en) | 2020-02-20 |
Family
ID=67809688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3108800A Pending CA3108800A1 (en) | 2018-08-17 | 2019-08-16 | Salts and crystal forms of omecamtiv mecarbil |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11465969B2 (https=) |
| EP (1) | EP3837009A1 (https=) |
| JP (3) | JP2021534138A (https=) |
| AU (2) | AU2019321573B2 (https=) |
| CA (1) | CA3108800A1 (https=) |
| MA (1) | MA53226A (https=) |
| MX (2) | MX2021001792A (https=) |
| WO (1) | WO2020037164A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5080970B2 (ja) | 2004-06-17 | 2012-11-21 | サイトキネティクス・インコーポレーテッド | 心疾患を治療するための置換尿素誘導体 |
| DK2970123T4 (da) | 2013-03-14 | 2026-01-26 | Amgen Inc | Krystallinsk dihydrochloridhydratsalt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf |
| SMT202100472T1 (it) | 2017-06-30 | 2021-09-14 | Amgen Inc | Sintesi di omecamtiv mecarbil |
| EP4512470A3 (en) | 2017-06-30 | 2025-04-23 | Amgen Inc. | Methods of treating heart failure with cardiac sarcomere activators |
| AU2018332887B2 (en) | 2017-09-13 | 2022-12-08 | Amgen Inc. | Bisamide sarcomere activating compounds and uses thereof |
| EP3594199B1 (en) | 2018-07-09 | 2020-07-01 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof |
| JP2021534138A (ja) * | 2018-08-17 | 2021-12-09 | アムジエン・インコーポレーテツド | オメカムチブメカルビルの塩及び結晶形態 |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| US20220348543A1 (en) * | 2019-09-19 | 2022-11-03 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| EP4031541A1 (en) * | 2019-09-19 | 2022-07-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| US20220402874A1 (en) * | 2019-10-09 | 2022-12-22 | Dr. Reddy's Laboratories Limited | Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof |
| US12194039B2 (en) | 2020-11-12 | 2025-01-14 | Amgen Inc | Methods of treating heart failure by administering omecamtiv mecarbil |
| WO2022177927A1 (en) | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
| JP7843295B2 (ja) | 2021-03-10 | 2026-04-09 | アムジェン インコーポレイテッド | オメカムチブメカルビルの合成 |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP5080970B2 (ja) | 2004-06-17 | 2012-11-21 | サイトキネティクス・インコーポレーテッド | 心疾患を治療するための置換尿素誘導体 |
| TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
| US20090192168A1 (en) * | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| CA2902424A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heterocyclic compounds and their uses |
| DK2970123T4 (da) | 2013-03-14 | 2026-01-26 | Amgen Inc | Krystallinsk dihydrochloridhydratsalt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf |
| WO2016123291A1 (en) | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| MX379899B (es) | 2015-06-26 | 2025-03-11 | Cytokinetics Inc | Terapia de combinacion de activador de miosina cardiaca e inhibidor de corriente if del nodo sinusal |
| EP4512470A3 (en) | 2017-06-30 | 2025-04-23 | Amgen Inc. | Methods of treating heart failure with cardiac sarcomere activators |
| SMT202100472T1 (it) | 2017-06-30 | 2021-09-14 | Amgen Inc | Sintesi di omecamtiv mecarbil |
| EP3594199B1 (en) | 2018-07-09 | 2020-07-01 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof |
| US11608318B2 (en) | 2018-07-12 | 2023-03-21 | Assia Chemical Industries Ltd. | Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl |
| JP2021534138A (ja) * | 2018-08-17 | 2021-12-09 | アムジエン・インコーポレーテツド | オメカムチブメカルビルの塩及び結晶形態 |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| EP4031541A1 (en) | 2019-09-19 | 2022-07-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| US20220348543A1 (en) | 2019-09-19 | 2022-11-03 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| WO2021070124A1 (en) | 2019-10-09 | 2021-04-15 | Dr. Reddy’S Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
| US20220402874A1 (en) | 2019-10-09 | 2022-12-22 | Dr. Reddy's Laboratories Limited | Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof |
| CN114929671B (zh) | 2020-01-03 | 2024-04-16 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
| CN115279349A (zh) | 2020-02-10 | 2022-11-01 | 安进股份有限公司 | 奥美卡替莫卡必尔片剂 |
| US12194039B2 (en) | 2020-11-12 | 2025-01-14 | Amgen Inc | Methods of treating heart failure by administering omecamtiv mecarbil |
| JP7843295B2 (ja) | 2021-03-10 | 2026-04-09 | アムジェン インコーポレイテッド | オメカムチブメカルビルの合成 |
-
2019
- 2019-08-16 JP JP2021507456A patent/JP2021534138A/ja active Pending
- 2019-08-16 WO PCT/US2019/046726 patent/WO2020037164A1/en not_active Ceased
- 2019-08-16 US US17/263,224 patent/US11465969B2/en active Active
- 2019-08-16 MX MX2021001792A patent/MX2021001792A/es unknown
- 2019-08-16 EP EP19762026.3A patent/EP3837009A1/en active Pending
- 2019-08-16 AU AU2019321573A patent/AU2019321573B2/en active Active
- 2019-08-16 MA MA053226A patent/MA53226A/fr unknown
- 2019-08-16 CA CA3108800A patent/CA3108800A1/en active Pending
-
2021
- 2021-02-12 MX MX2023013372A patent/MX2023013372A/es unknown
-
2022
- 2022-09-02 US US17/929,645 patent/US11926592B2/en active Active
-
2024
- 2024-06-04 JP JP2024090471A patent/JP2024123028A/ja not_active Withdrawn
-
2025
- 2025-04-14 JP JP2025066074A patent/JP2025108571A/ja active Pending
- 2025-05-29 AU AU2025204014A patent/AU2025204014A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024123028A (ja) | 2024-09-10 |
| US20240199550A1 (en) | 2024-06-20 |
| EP3837009A1 (en) | 2021-06-23 |
| JP2025108571A (ja) | 2025-07-23 |
| AU2019321573B2 (en) | 2025-05-29 |
| US20210221771A1 (en) | 2021-07-22 |
| MA53226A (fr) | 2021-11-24 |
| US11465969B2 (en) | 2022-10-11 |
| MX2021001792A (es) | 2021-05-27 |
| AU2019321573A1 (en) | 2021-03-04 |
| US20230108971A1 (en) | 2023-04-06 |
| JP2021534138A (ja) | 2021-12-09 |
| MX2023013372A (es) | 2023-11-27 |
| AU2025204014A1 (en) | 2025-06-19 |
| US11926592B2 (en) | 2024-03-12 |
| WO2020037164A1 (en) | 2020-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11926592B2 (en) | Salts and crystal forms of omecamtiv mecarbil | |
| US12275704B2 (en) | Heterocyclic compounds and their uses | |
| US10590089B2 (en) | Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide | |
| TW201514165A (zh) | Ｄ-葡萄糖醇，１-脫氧-１-（甲胺基）-，-１-（６-胺基-３，５-二氟吡啶-２-基）-８-氯-６-氟-１，４-二氫-７-（３-羥基氮雜環丁烷-１-基）-４-側氧基-３-喹啉羧酸的結晶形態與其製備程序 | |
| TWI857027B (zh) | 心肌肌鈣蛋白活化劑之多晶型物 | |
| US12612366B2 (en) | Salts and crystal forms of omecamtiv mecarbil | |
| US20230040902A1 (en) | Pharmaceutical Formulation Comprising Cibenzoline or Salt Thereof | |
| WO2024149834A1 (en) | Polymorphs of the hydrobromide salt of linaprazan glurate | |
| WO2016155631A1 (zh) | 托吡司他的新晶型及其制备方法 | |
| CA3210612C (en) | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220908 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240729 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251024 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260205 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260211 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260211 |